Octane's Cocoon cell therapy system integrates upstream and downstream processing including cell source isolation and cell expansion, cell collection, cell washing and final product formation, in a closed, single-use disposable cassette. By integrating multiple steps in combination with biosensor feedback, this highly innovative technology, unlike other bioreactor systems, is expected to permit substantial upscaling of patient-scale cell manufacturing capabilities, allowing streamlined production of cell therapies under GMP conditions.
With the Cocoon system available as a routine evaluation platform, the teams at BrainStorm and Octane are now working to further refine development of the cassettes that will be used in the automated bioreactors to manufacture NurOwn stem cells.
"The development of an advanced, scalable and automated system for the manufacture of NurOwn for commercial supply is important goal for BrainStorm," stated Chaim Lebovits, CEO of BrainStorm. "The progress we have made, by leveraging Octane's Cocoon system, moves us one step closer to our ultimate goal of providing patients and physicians with an improved standard of care for treating neurodegenerative diseases."
Dr. Timothy Smith, CEO of Octane Biotech further commented, "The Octane Cocoon platform was designed to automate the complex production sequences in autologous cell manufacturing. Our customization of the Cocoon cassette to incorporate BrainStorm's proprietary NurOwn technology is a perfect example of how we closely interact with our corporate clients and partners. We are pleased to be working with BrainStorm, and look forward to helping advance their important work."
Octane Biotech has partnerships with a number of leading healthcare companies and academic centers. The Cocoon technology is currently being evaluated in a partnership with Lonza Group Ltd. with the goal of developing the platform for a wide range of autologous and matched-allogenic cell therapy products.
About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn has been administered to over 60 patients with ALS in clinical trials conducted in Israel and the United States, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial at three major clinical centers in the United States. For more information, visit the company's website at www.brainstorm-cell.com.
About Octane Technology Octane Cocoon™ is an integrated turnkey cell production solution that can be configured as a compact but powerful system with a small footprint, or as a multi-patient system for ultra-efficient, enterprise-level deployment. Please visit www.octaneco.com/cocoon for more information about the regenerative medicine platform solutions available from Octane.
About Octane Biotech Inc. Octane is a medical technology company with the most advanced bioreactors, bioprocesses and biomaterials for regenerative medicine. We partner with cell therapy and medical device companies to develop and manufacture game-changing regenerative medicine solutions. Through our product customization and commercialization services, we adapt our product lines to specialized clinical applications. By doing what we do, we pioneer technologies that transform the lives of patients and create market-leading business opportunities for our global commercial partners. More information is available at www.octaneco.com
Forward-looking statements
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. These forward-looking statements are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. CONTACTS BrainStorm Uri Yablonka Michael Rice Chief Operating Officer LifeSci Advisors, LLC BRAINSTORM CELL THERAPEUTICS INC. Phone: (646) 597-6979 201-488-0460 mrice@lifesciadvisors.com uri@brainstorm-cell.com Octane Octane Biotech Inc. Executive Assistant Renee Thibodeau Tel 613 634 6345 x200 Fax 613 634 5436 renee.thibodeau@octaneco.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brainstorm-and-octane-biotech-announce-success-in-cocoon-application-development-based-on-customized-bioreactor-for-nurown-stem-cells-300185953.html
Contacts
BrainStorm
Media:
Investors:
Uri Yablonka
Michael Rice
Chief Operating Officer
LifeSci Advisors, LLC
BRAINSTORM CELL THERAPEUTICS INC.
Phone: (646) 597-6979
201-488-0460
mrice@lifesciadvisors.com
uri@brainstorm-cell.com
Octane
Octane Biotech Inc.
Executive Assistant
Renee Thibodeau
Tel 613 634 6345 x200
Fax 613 634 5436
renee.thibodeau@octaneco.com